Evaluating the role of vepdegestrant in metastatic breast cancer

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, comments on the potential of vepdegestrant as a novel endocrine backbone in the treatment of metastatic breast cancer, particularly in combination with CDK4/6 inhibitors, and its potential for use in earlier lines of therapy. The findings from the VERITAC-2 trial (NCT05654623) may have an impact in the second and third line settings, where a majority of patients had only received one prior treatment in the metastatic setting. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.